Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study.
Locasciulli A, Bruno B, Rambaldi A, Saracco P, Dufour C, Finelli C, Sica S, Varotto S, Arcese W, Locatelli F, Soligo D, Bacigalupo A; GITMO prospective randomized study. Locasciulli A, et al. Among authors: finelli c. Haematologica. 2004 Sep;89(9):1054-61. Haematologica. 2004. PMID: 15377466 Clinical Trial.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Voso MT, et al. Among authors: finelli c. Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154. Ann Oncol. 2017. PMID: 28368509 Free article. Clinical Trial.
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.
Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT. Falconi G, et al. Among authors: finelli c. Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291338 Free PMC article. No abstract available.
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Marcellari A, Roubert B, Rose C. Gattermann N, et al. Among authors: finelli c. Haematologica. 2012 Sep;97(9):1364-71. doi: 10.3324/haematol.2011.048546. Epub 2012 Mar 14. Haematologica. 2012. PMID: 22419577 Free PMC article. Clinical Trial.
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.
Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V. Messa E, et al. Among authors: finelli c. Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076178 Free PMC article. Clinical Trial. No abstract available.
All-trans retinoic acid in the treatment of myelodysplastic syndromes.
Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S. Visani G, et al. Among authors: finelli c. Leuk Lymphoma. 1995 Oct;19(3-4):277-80. doi: 10.3109/10428199509107898. Leuk Lymphoma. 1995. PMID: 8535219 Clinical Trial.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Among authors: finelli c. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
225 results